Podzamczer Palter, D., & group, E. s. (2019). Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
Citação norma ChicagoPodzamczer Palter, Daniel, y EMERALD study group. Week 96 Efficacy and Safety Results of the Phase 3, Randomized EMERALD Trial to Evaluate Switching From Boosted-protease Inhibitors Plus Emtricitabine/tenofovir Disoproxil Fumarate Regimens to the Once Daily, Single-tablet Regimen of Darunavir/cobicistat/emtricitabine/tenofovir Alafenamide (D/C/F/TAF) in Treatment-experienced, Virologically-suppressed Adults Living With HIV-1. 2019.
Citação norma MLAPodzamczer Palter, Daniel, y EMERALD study group. Week 96 Efficacy and Safety Results of the Phase 3, Randomized EMERALD Trial to Evaluate Switching From Boosted-protease Inhibitors Plus Emtricitabine/tenofovir Disoproxil Fumarate Regimens to the Once Daily, Single-tablet Regimen of Darunavir/cobicistat/emtricitabine/tenofovir Alafenamide (D/C/F/TAF) in Treatment-experienced, Virologically-suppressed Adults Living With HIV-1. 2019.